EU approves new use for Pfizer's Enbrel and Roche's Avastin; sales surge for Arena's obesity drug Belviq;

@FiercePharma: Best-read news yesterday: Express Scripts hits Amgen, Zogenix as it punts another 25 drugs. Story | Follow @FiercePharma

@TracyStaton: Tops @FiercePharma over the weekend: Top Sanofi exec departs amid struggles in diabetes franchise. Report | Follow @TracyStaton

@EricPFierce: Novartis hangs 'For Sale' sign on U.S. plant as it prepares to close and sale facility and lay off 500. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Ackman's crusade for Valeant-Allergan combo gets a key nod from proxy advisers. Report | Follow @CarlyHFierce

> Pfizer's ($PFE) Enbrel scored a European nod to treat a rare inflammatory joint disorder at early stages of the disease. Report

> Arena Pharmaceuticals ($ARNA) reported a 43% rise in second-quarter sales of its obesity drug Belviq as DTC ads and a beefed-up sales force gained momentum. Report (reg. req.)

> Sanofi ($SNY) tapped India's Emcure Pharmaceuticals to market its oncology drugs Taxotere, Jevtana, Fludara and Fasturtec in that country. Report

> It's official: Roche ($RHHBY) has won approval to market Avastin in Europe as a treatment for recurrent ovarian cancer resistant to platinum-based chemo. Release | Report

> Drugstore owner The Walgreen Co. ($WAG) will buy the 55% stake in U.K. retailer Alliance Boots that it does not own but has decided against moving its legal domicile to Europe in a tax inversion plan. Story (sub. req.)

> Cubist Pharmaceuticals ($CBST) has recalled vials of its antibiotic Cubicin after glass particles were found in some. Story

> U.S.-based generic drugmaker Alvogen says it will pay $187 million in cash for South Korea's Dream Pharma. Story

Medical Device News

@FierceMedDev: ICYMI yesterday: Home healthcare design considerations addressed in FDA final guidance. Story | Follow @FierceMedDev

@StacyALawrence: Philips, Accenture create brain wave app for immobilized patients. Article | Follow @StacyALawrence

@VarunSaxena2: Stentys ditches bare metal stents as customers move to drug-eluting versions. FierceDrugDelivery story | Follow @VarunSaxena2

@MichaelGFierce: Thin and strong, graphene sheets form spheres spontaneously for drug release. Story | Follow @MichaelGFierce

@EmilyWFierce: Quick point-of-care devices could be the next "holy grail" in detecting infectious diseases like Ebola. More from NBC News | Follow @EmilyWFierce

> Wright expects profitability by yearend with ankle system launch. Article

> Scientist robot gets venture funding from Omega. Item

> Siemens and Cerner teaming up to develop new med tech as part of $1.3B deal. Report

Biotech News

@FierceBiotech: New special report: The top 15 late-stage blockbusters in the pipeline. Feature | Follow @FierceBiotech

@JohnCFierce: ICYMI yesterday: How big is Novartis's LCZ696 heart drug? Experts bet on a key number. Article | Follow @JohnCFierce

@DamianFierce: Auris Medical prices $56M IPO, ushers in the era of $EARS on Wall Street. Release (PDF) | Follow @DamianFierce

> Regeneron hits the gas on R&D, pouring cash into a blockbuster pipeline. More

> Auris pulls off a $56M IPO to bankroll its ear treatments. Report

> Sarepta leaps into Ebola spotlight with a shelved therapy. Story

> Cytori shares slammed as safety concerns halt stem cell trials. Article

Drug Delivery News

> BD launches AutoShield Duo pen for diabetics. Report

> BioDelivery Sciences International to add 80 patients to clinical trial of Clonidine Topical Gel. Item

> Carnegie Mellon team creates self-assembling nanofibers for shaped delivery vehicles. Article

> Biodegradable film strip enabling 14 months of drug delivery prototyped by MIT team. Story

> Stentys ditches bare metal stents as customers move to drug-eluting versions. Article

Diagnostics News

> Johns Hopkins group scrutinizes possible biomarker for suicide risk. News

> Dx industry is cautious, wary and diplomatic in the face of FDA's push to regulate LDTs. Report

> MGC Diagnostics completes Belgian M&A deal with an eye on globalization. More

> Exosome Diagnostics replaces CEO and relocates as it preps for commercialization. Article

> OncoCyte rolls out massive trial for bladder cancer Dx. Story

Pharma Marketing News

> Third to market may still be a charm for Lilly, BI's new diabetes med Jardiance. More

> GSK relaunches COPD patient site with blockbuster sales on the line. Item

> The formularies are here! Brace yourselves for the 48 new exclusions. Report

> J&J Baby aims to turn ingredients scandal into sales with 'transparent' ad campaign. Story

> Teva eyes 'hard switch' to hit Copaxone goals if the soft sell isn't enough. Article

And Finally... A Wisconsin man was sentenced to a year in prison for making erectile dysfunction drugs in his home lab from active ingredients he bought from China. Story

Suggested Articles

A suspected cancer-causing impurity that has been found in some blood pressure medicines has now shown up in Zantac and some OTC antacids.

Roche is steamrolling with Ocrevus, and to maintain that lead, its touting long-term data that show the earlier it’s given, the better patients do.

New data shows a significant reduction in relapse rates in patients taking Novartis' repurposed cancer drug ofatumumab.